Prognostic significance of MAPK10 in HCC was also studied in this cohort of 59 patients with follow-up data, which indicated that the expression of MAPK10 was extremely correlative with OS of patients (log rank = 7.123, P = 0.008): the median OS time in MAPK10-negative subgroup (n = 23) and MAPK10-positive subgroup (n = 36) were 10.86 months (95% CI [5.927–15.792]) and 24.040 months (95% CI [17.511–30.568]) respectively (Fig. 2). This evidence concerns the gene MAPK10 and hepatocellular carcinoma.